11.25.13
The FDA has approved Johnson & Johnson's Olysio ( assimeprevir) as a treatment for chronic hepatitis C virus infection. Olysio is a protease inhibitor that blocks a specific protein needed by the virus to replicate, and is used in combination with interferon, given by injection, and ribavirin. Olysio was shown in clinical trials to cure patients with a shorter duration of treatment.